Aarti Drugs reports strong financial performance for Q2 2025

Aarti Drugs Limited reported a total standalone income of INR 57,910 Lacs for the quarter ended September 30, 2025, up from INR 54,347 Lacs in the same quarter of the previous year. The standalone net profit after tax for the quarter was INR 4,178 Lacs, showing a notable increase compared to INR 3,039 Lacs in Q2 2024. For the half-year ended September 30, 2025, standalone total income reached INR 110,044 Lacs, with a net profit after tax of INR 9,042 Lacs.

On a consolidated basis, the total income for the quarter stood at INR 65,288 Lacs, and the consolidated net profit after tax was INR 4,516 Lacs. For the half-year, consolidated total income was INR 124,370 Lacs, with a net profit after tax of INR 9,913 Lacs. Basic earnings per share (EPS) for the quarter ended September 30, 2025, was INR 4.58 (standalone) and INR 4.95 (consolidated).

The company also noted the completion of a buyback of 665,000 equity shares on September 24, 2024, at INR 900 per share. Additionally, Aarti Drugs' new manufacturing plant at Sayakha, Gujarat, commenced commercial operations on September 4, 2025.